Oral Wegovy Launches in 2026: $149/Month Price and What It Means

Novo Nordisk quietly rewrote the weight-loss pricing playbook in the first weeks of 2026. Oral Wegovy, the tablet version of semaglutide approved by the FDA in December 2025 and launched commercially in January, is now available through the company’s direct-to-patient NovoCare program for $149 a month. The retail cash price without NovoCare is $349. For context, the injectable Wegovy launched at a retail price that regularly cleared $1,300 per month before coupons. A tablet at $149 is a different product category.

This is the first time Novo Nordisk has put an oral GLP-1 on the US market specifically for weight loss. Rybelsus, the company’s earlier oral semaglutide, has been around since 2019, but it is approved for type 2 diabetes and has a different dose profile. Oral Wegovy is its own approval, its own label, and its own pricing strategy.

The efficacy numbers

In the pivotal trial, patients who adhered to the full regimen lost an average of 16.6% of body weight. That is slightly higher than the roughly 15% that injectable Wegovy has posted in its own trials, which surprised a lot of people. The oral formulation uses an absorption enhancer to get semaglutide through the stomach lining intact, and the common assumption has always been that injections would deliver more consistent bioavailability. In practice, the tablet looks competitive at a high dose.

The caveat is the word “adhered.” Oral Wegovy has to be taken first thing in the morning with no more than four ounces of plain water, at least 30 minutes before any food, drink, or other medication. Miss the fasting window and absorption drops significantly. The 16.6% number assumes patients actually follow those instructions. Real-world adherence in the wild may be lower, particularly in patients who also take thyroid meds or proton-pump inhibitors in the morning.

Why the $149 price matters

The NovoCare self-pay tier is aimed squarely at two groups: patients without coverage, and patients whose plans require step therapy that blocks them from going straight to Wegovy. At $149 a month, the annual cost of a year of therapy is roughly $1,800, which puts it in the same ballpark as generic cholesterol or blood pressure medications. That is a dramatic shift for a branded GLP-1.

It also applies real pressure to compounding pharmacies that have been filling the gap with copies of semaglutide at around $200 to $300 per month. If a patient can buy the FDA-approved branded product at roughly the same price, the compounding business case gets harder, especially given the FDA’s ongoing scrutiny of large-scale 503B compounding operations for GLP-1 copies.

Why oral matters

Roughly one in four adults in the United States has a meaningful fear of needles. For some of them, the weekly self-injection required by injectable GLP-1s is a hard stop. Others tolerate the injection fine but drop the prescription when they travel, because they do not want to deal with refrigeration or TSA. A daily tablet removes both barriers.

There is also an adherence argument on the other side. A weekly injection is, for most patients, easier to remember than a daily fasting pill. Whether the patient pool shifts toward the tablet depends on individual preference, not a single right answer.

Oral Wegovy vs Rybelsus

A common question at the pharmacy counter is whether Rybelsus and oral Wegovy are the same thing. They are not. Both are oral semaglutide from Novo Nordisk, but the doses, the indications, and the coverage buckets are different. Rybelsus is approved only for type 2 diabetes. Oral Wegovy is approved specifically for chronic weight management, at higher active doses. A patient with an obesity diagnosis cannot just stack Rybelsus tablets to hit the Wegovy dose range, both because the escalation is different and because insurance will flag the off-label use.

Competition on the horizon

Eli Lilly is closing in with orforglipron, a small-molecule oral GLP-1 agonist that does not require a fasting window or an absorption enhancer. Phase 3 results have landed with an average weight loss of around 12.4%, which is below oral Wegovy’s 16.6% but still clinically meaningful. Lilly is targeting a commercial launch around the second quarter of 2026. If the label lands without major issues, that gives Novo roughly one quarter alone on the oral shelf before the first direct competitor shows up.

The interesting wrinkle is the adherence tradeoff. Orforglipron at 12.4% with no fasting requirement may actually outperform oral Wegovy at 16.6% with strict fasting, once real-world data starts coming back. Head-to-head trials are not scheduled, but the market will generate its own comparison quickly.

If you are thinking through whether oral Wegovy is the right fit, the semaglutide profile has the full dosing and side-effect breakdown, and our semaglutide vs tirzepatide comparison stacks it against the main alternative. You can estimate your own total cost using the cost calculator.